- Home
- ACRS vs PGC Comparison
ACRS vs PGC Comparison
Compare ACRS & PGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRS | PGC |
|---|---|---|
| Founded | 2012 | 1921 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.5M | 836.7M |
| IPO Year | 2015 | 1997 |
Fundamental Metrics
Financial Performance| Metric | ACRS | PGC |
|---|---|---|
| Price | $6.28 | $45.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $10.20 | ★ $40.50 |
| AVG Volume (30 Days) | ★ 1.9M | 176.4K |
| Earning Date | 05-07-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 0.48% |
| EPS Growth | ★ 69.01 | 13.51 |
| EPS | N/A | ★ 1.65 |
| Revenue | $1,683,000.00 | ★ $282,995,000.00 |
| Revenue This Year | N/A | $32.39 |
| Revenue Next Year | $4.24 | $12.64 |
| P/E Ratio | ★ N/A | $27.31 |
| Revenue Growth | N/A | ★ 24.05 |
| 52 Week Low | $1.74 | $24.71 |
| 52 Week High | $6.52 | $49.14 |
Technical Indicators
Market Signals| Indicator | ACRS | PGC |
|---|---|---|
| Relative Strength Index (RSI) | 61.76 | 43.76 |
| Support Level | $4.13 | $44.85 |
| Resistance Level | $6.52 | $46.57 |
| Average True Range (ATR) | 0.36 | 0.99 |
| MACD | 0.03 | -0.11 |
| Stochastic Oscillator | 83.72 | 20.36 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
About PGC Peapack-Gladstone Financial Corporation
Peapack Gladstone Financial Corp is a bank holding company. Through its subsidiaries, the company offers various wealth management, investment banking, and commercial and personal banking solutions to its clients. The company has two reportable segments: Banking, which generates the maximum revenue, and Wealth Management. The Banking segment includes commercial, commercial real estate, multifamily, residential, and consumer lending activities; treasury management services; escrow management; deposit generation; operation of ATMs; telephone and internet banking services; credit card services, etc. The Wealth Management segment offers investment management services for individuals and institutions; personal trust services; and other financial planning and advisory services.